Betamed Exim Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 29-06-2024
- Paid Up Capital ₹ 0.10 M
as on 29-06-2024
- Company Age 7 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 559.29%
(FY 2023)
- Profit 193.86%
(FY 2023)
- Ebitda 257.66%
(FY 2023)
- Net Worth 24.16%
(FY 2023)
- Total Assets 61.63%
(FY 2023)
About Betamed Exim
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Sanjeev Nischal, Minakashi Nischal, and Namit Nischal serve as directors at the Company.
- CIN/LLPIN
U33309DL2017PTC323485
- Company No.
323485
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
11 Sep 2017
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
New Delhi, Delhi, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Betamed Exim Private Limited offer?
Betamed Exim Private Limited offers a wide range of products and services, including Orthopedic Equipment & Supplies, Orthopedic Trauma Implants, Spinal Implants, Hip Prosthesis, Orthopedic Instruments.
Who are the key members and board of directors at Betamed Exim?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sanjeev Nischal  | Director | 11-Sep-2017 | Current |
| Minakashi Nischal | Director | 26-Feb-2018 | Current |
| Namit Nischal | Director | 10-Jul-2020 | Current |
Financial Performance of Betamed Exim.
Betamed Exim Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 559.29% increase. The company also saw a substantial improvement in profitability, with a 193.86% increase in profit. The company's net worth Soared by an impressive increase of 24.16%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Betamed Exim?
In 2023, Betamed Exim had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Beta Surgicare Private LimitedActive 14 years 11 monthsSanjeev Nischal and Minakashi Nischal are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Betamed Exim?
Unlock and access historical data on people associated with Betamed Exim, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Betamed Exim, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Betamed Exim's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
